journal description

The Journal of Medical Research and Innovation (JMRI) is an award-winning and open peer-reviewed journal which covers all aspects of Medicine including cellular biology, zoology and futuristic medicine (Robotics and Artificial Intelligence in medicine). The journal will feature original research, reviews, editorials, case studies, brief communications, opinions/views, poster presentations and audios & videos. This will be of interest to medical practitioners, clinical educators, nurse practitioners and other healthcare professionals involved in the care of patients.

The journal publishes at least two issues (Bi-Annually. First issue in January and Second in July) each year. Articles are published online when ready for publication (Continuously) as Article in Press. Additional issues may be published for special events (e.g. conferences) and when special themes are addressed. 

ISSN: 2456-8139, Editor in Chief: Dr. Varshil Mehta, Publisher: Scientific Scholar (from April, 2021)
Acceptance Rate (2020): 47.5%, Access: Open Access from 2020, Article Processing Charge: Know more
Index Copernicus Value-2019: 96.75, Impact Factor (Dimensions): 1.55H-Index (Google Scholar): 9
Frequency: Bi-Annual, Abbreviation: J Med Res Innov, Contact: editorialteam@jmrionline.com



Original Article

Incidence of Hashimoto Thyroiditis Among Libyans: A Retrospective Epidemiological Study

by Atia A., Alathream R., Al-Deib A.

Summary: Background and aims. Hashimoto's disease is an autoimmune disorder in which the body produces antibodies that attack the thyroid gland, leading to chronic inflammation, destruction of the gland, and hypothyroidism. This study aimed to assess the epidemiology of this disease among Libyan patients. Methods. A cross-sectional retrospective study conducted from June 2012 to April 2020 in order to examine the anti TPO level among Libyan population. Data was collected from eastern and western part of Libya, and were analyzed from available sample for 244 apparently patients with thyroid disorders collected from different private clinic’s laboratories. The analysis for serum anti-TPO was done by electrochemiluminescence protein binding assay (ECLIA) using Roche diagnostics and Cobas e411 analyzer. Results. The current results showed that females predominate the study, and most of them were in the age group of (>40) years old. About 49.18% of these cases were suffering from Hashimoto's disease (High ATPO level). The mean value of anti-TPO status among females was (0.5±2) nmol/L, while among males it was (0.45±3) nmol/L. Significantly, more women (81.66%) had Anti- TPO Above (34 IU/ml), compared to (18.33%) of male participants. Conclusion. Hashimoto disease is common among patients with thyroid dysfunction especially females. Our findings suggest that different interventional strategies are needed to reduce the chances of developing Hashimoto’s and its associated negative health outcomes in Libya.

Original Article

A study on the quality of life among stroke survivors: A cross sectional study

by Sahu R., Kumar S., Yadav P.

Summary: Background: The World Health Organization defines - Health as a “state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.”

Original Article

The effect of double-carbapenem therapy on mortality rates and microbiological cure rates in patients diagnosed with carbapenem-resistant Klebsiella pneumoniae infections in comparison to monotherapy and currently used combinations of antibiotics

by Moody R.

Summary: Infection with the bacteria carpamenease-producing Klebsiella pneumoniae represents a significant cause of mortality in hospitalised patients. These multidrug resistant bacteria are resistant to currently used antibiotics as a result of carbapenemase production. Dual carbapenem therapy has been proposed as a valid therapeutic option, this therapy combines two carbapenem antibiotics, with one acting as a suicide inhibitor allowing the subsequent carbapenem to exert a bactericidal effect.

Editorial

Povidone iodine hookah therapy for the treatment of COVID-19 and other respiratory viruses: A hypothesis we must test

by Gandhi R.

Summary: Povidone – Iodine has been known to have strong bactericidal and virucidal properties for a long time. It has been in clinical use as an antiseptic agent for over fifty years. Now a new indication for this old drug is recommended as Hookah therapy. It is hypothesized that in this form it will be an effective therapeutic agent to kill the coronavirus (SARS-COV2) or significantly inhibit its multiplication to achieve a cure. Details of treatment and dosage form are presented.

Original Article

Eating behaviors of American adults during the COVID-19 pandemic

by Kandiah J., Saiki D., Jones J.

Summary: The objective was to assess the impact of the COVID-19 pandemic on eating behaviors of a cross section of the US adult population. Participants (N=844) completed a survey via Amazon Mechanical Turk which evaluated frequency of consumption of five food categories - mixed dishes, salty, sweet, creamy foods and beverages during perceived stress. Physical, emotional and psychological self-care and demographics were also collected. Males eating behaviors especially mixed dishes, sweet foods, and creamy foods decreased when stressed. However, in females there was an increase in the consumption of sweet and creamy foods. When compared to their counterpart, there was a reduction in food choices among minorities and Hispanics. Participants with higher BMI had increased eating behaviors of mixed dishes, salty, and sweet foods. The physical self-care scale revealed there was limited consumption of sweet foods but the psychological self-care demonstrated that there was an increase in creamy food intake

Original Article

Health care professional knowledge and attitude towards the use of digital technologies in provision of maternal health services at Tumbi regional referral hospital in Tanzania

by Thadeus W., Mushi L.

Summary: In recent years Tanzania introduced digital technologies in health industry where several initiatives such as Government of Tanzania, Hospital Management Information System (GoT-HoMIS) along other digital devices are taken to ensure quality services delivery. The purpose of this study was to assess Health Care Providers (HCPs) knowledge and attitude towards the use of Digital Health Technology (DHT) in provision of maternal health services at Tumbi Regional Referral Hospital (TRRH).

New website

The journal of Medical Research and Innovation will now be available on our new site (www.jmedresinnov.com).

All previous articles will be available on the archives section of www.jmrionline.com.


JMRI will now be published by Scientific Scholar

We are pleased to say that from next issue (Volume 5, Issue 2), the Journal of Medical Research and Innovation shall be published by Scientific Scholar (https://scientificscholar.com), an Indo-American publisher.


Index Copernicus Value for 2018 has been increased to 99.05 from 77.03 (2017 value)

Index Copernicus Value for 2018 has been increased to 99.05 from 77.03 (2017 value).

Link: https://journals.indexcopernicus.com/search/details?id=47018&lang=en

Congrats to JMRI team and its authors.


Subscription/Printing services

The subscription/printing for/of the Journal of Medical Research and Innovation shall be managed/handled by AkiNik Publications, New Delhi, India. The subscription charges will be ₹3000 or $120 per year.  

All subscriptions are payable in advance and all rates include postage and taxes. Issues will be sent on receipt of
payment. Subscriptions are entered on an annual basis and are subject to renewal in subsequent years.

Please fill this form: https://www.akinik.com/SubscriptionForm.pdf and send this form with payment to (By speed post/courier only):
Subscription Manager, AkiNik Publications
H. No. 169, Pocket C-11, Sector-3, Rohini, New Delhi-110085, India.
Ph.:+91-9711224068; E-mail: info@akinik.com; web.: https://www.akinik.com



Average peer reviewing time of JMRI

The current average peer reviewing time is appx. 7 weeks. However, the average time for the first decision made is appx. 5 weeks.

There is a possibility that the time for your paper may vary, if we do not find relevant reviewers for your paper. However, you can help us with this regard by providing the names of two reviewers who can potentially review your paper (Cannot be from your institution or who have worked with you in last one year).

Please bear with us, as we try our best to find reviewers in time. But, we promise to provide a fair and timely experience to every one of you.


JMRI shall now display and use CrossMark

download_(1).jpg

We are pleased to say that JMRI shall now display CrossMark on each article published henceforth (may be even all those are already published so far).  This will enable us to provide current information of each published paper. Read more about crossmark at https://www.crossref.org/services/crossmark/


No publication fees for the articles submitted in 2019

There shall be no charges for the entire 2019 year. Submit your paper soon. Lets make JMRI even better. Cheers to Researchers, Cheers to JMRI !!! 


Medkrux Research Group

After getting many request to start a research group, we have finally started one for all medicos. To read more kindly visit: http://medkrux.com/research-group.


More Updates